{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib+phosphate&page=5", "query": { "intervention": "ruxolitinib phosphate", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 290, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib+phosphate&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib+phosphate&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T16:38:35.547Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04281498", "title": "Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated/Blast-phase Myeloproliferative Neoplasm", "Chronic-phase Myelofibrosis", "IDH2 Mutation" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-01-14", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04281498" }, { "nct_id": "NCT04414514", "title": "Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Ruxolitinib 1.5% Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 6, "start_date": "2022-10-13", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04414514" }, { "nct_id": "NCT04817007", "title": "A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "BMS-986158", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2021-03-22", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 8, "location_summary": "Newport Beach, California • Lake Mary, Florida • New Orleans, Louisiana + 5 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04817007" }, { "nct_id": "NCT04896385", "title": "A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vitiligo" ], "interventions": [ { "name": "Ruxolitinib cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-06-23", "completion_date": "2023-07-10", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 6, "location_summary": "Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04896385" }, { "nct_id": "NCT03935555", "title": "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-Polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)" ], "interventions": [ { "name": "PU-H71", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Samus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2019-08-12", "completion_date": "2022-11-04", "has_results": false, "last_update_posted_date": "2022-11-17", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 3, "location_summary": "Larkspur, California • Los Angeles, California • Houston, Texas", "locations": [ { "city": "Larkspur", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03935555" }, { "nct_id": "NCT02101268", "title": "Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-polycythemia Vera (Post-PV)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Best Available Therapy (BAT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2014-06-19", "completion_date": "2019-04-25", "has_results": true, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 13, "location_summary": "Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101268" }, { "nct_id": "NCT03515200", "title": "Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission" ], "interventions": [ { "name": "Palbociclib Oral Capsule", "type": "DRUG" }, { "name": "Intrathecal Triple Therapy", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2018-04-20", "completion_date": "2020-07-29", "has_results": false, "last_update_posted_date": "2020-09-01", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515200" }, { "nct_id": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2014-06-09", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152956" }, { "nct_id": "NCT01822756", "title": "An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Pancreatic Cancer" ], "interventions": [ { "name": "ruxolitinib", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2013-04", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2018-02-12", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Gainesville, Florida • Sarasota, Florida + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01822756" }, { "nct_id": "NCT04996160", "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric", "Relapsed Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanja Andrea Gruber", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 2, "start_date": "2021-07-09", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-08T16:38:35.547Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996160" } ] }